Reperfuzionnaya terapiya pri ishemicheskom insul'te


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the review of numerous studies of new technologies of reperfusion therapy in the early hours of ischemic stroke, which are being actively implemented in our country, qualitatively change the approach to the management of patients and significantly improve patient outcomes, causing reduction in mortality and an increase in the number of patients with good restoration of neurological function.

全文:

受限制的访问

参考

  1. http://www.eso-stroke.org.
  2. Del Zoppo G.J., Saver J.L., Jauch E.C., Adams H.P Jr. and on behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009;40:2945.
  3. Tissue Plasminogen Activator For Acute Ishemic Stroke. New En J Med 1995;333(24).
  4. Hacke W., Kaste M., Fieschi C., et al, for the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274(13).
  5. Hacke W., Kaste M., Fieschi C., et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352(Issue 9136):1245-51.
  6. Clark W.M., Viessman S., Albers G.W., et al., for the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999;282:2019-26.
  7. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
  8. Hacke W., Kaste M., Bluhmki E., et al., for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med 2008;359:1317-29.
  9. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. The IST-3 collaborative group. Lancet 2012;379:2352-63.
  10. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial - Italy (Mast-I) Group. Lancet 1995;346(8989):1509-14.
  11. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicentre Acute Stroke Trial - Europe Study Group. N Engl J Med. 1996 Jul 18;335(3):145-50.
  12. Yasaka M., Chambers B.R., Davis S.M., Donnan G.A. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology. 1998;50(3):626-32.
  13. Furlan A.J., Eyding D., Albers G.W., et al., for the DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset. Stroke 2006;37:1227-31.
  14. Hacke W., Albers G., Yasir Al-Rawi, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A Phase II MRI - Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase. Stroke 2005;36:66-73.
  15. The Lancet Neurology 2009;8(Issue 2):141-50.
  16. www.controlled-trials.com.
  17. del Zoppo G.J., Higashida R.T., Furlan A.J., et al. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. Stroke 1998;29:4-11.
  18. Lewandowski C.A., Frankel M., et al. Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-605.
  19. Combined Intravenous and Intra-arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study. The IMS Study Investigators. Stroke 2004; 35:904-12.
  20. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35.
  21. www.ims3.org.
  22. Lisboa R.C., Jovanovic B.D., Alberts M.J. Analysis of the Safety and Efficacy of Intra-Arterial Thrombolytic Therapy in Ischemic Stroke. Stroke 2002;33:2866-71.
  23. Lee M., Hong K-S., Saver J.L. Efficacy of Intra-Arterial Fibrinolysis for Acute Ischemic Stroke Meta-Analysis of Randomized Controlled Trials. Stroke 2010;41:932-37.
  24. Starkman P.S., Duckwiler G.R., Grobelny T., et al. A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004;35:2848-54.
  25. Smith W.S., Sung G., Saver J., et al., for the Multi MERCI Investigators. Mechanical Thrombectomy for Acute Ischemic Stroke Final Results of the Multi MERCI Trial. Stroke 2008;39:1205-12.
  26. The Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial. Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease. Stroke 2009; 40:2761-68.
  27. Cao F., et al. Delayed neuronal cell death in brainstem after transient brainstem ischemia in gerbils. BMC Neurosci 2010;11:115.
  28. Hata R., et al. Differential vulnerability in the hindbrain neurons and local cerebral blood flow during bilateral vertebral occlusion in gerbils. Neuroscience 1993;56(2):423-39.
  29. Brandt T. Diagnosis and thrombolytic therapy of acute basilar artery occlusion: a review. Clin Exp Hypertens 2002;24(7-8):611-22.
  30. Becker K.J., et al. Intraarterial thrombolysis in vertebrobasilar occlusion. AJNR Am J Neuroradiol 1996;17(2):255-62.
  31. Brandt T., et al. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996;27(5):875-81.
  32. Eckert B., et al. Endovascular therapy of acute vertebrobasilar occlusion: early treatment onset as the most important factor. Cerebrovasc Dis 2002;14(1):42-50.
  33. Hacke W., et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19(10):1216-22.
  34. Lindsberg P.J., Mattle H.P. Therapy of basilar artery occlusion: a systematic analysis comparing intraarterial and intravenous thrombolysis. Stroke 2006;37(3):922-28.
  35. Pfefferkorn T., et al. Drip, ship, and retrieve: cooperative recanalization therapy in acute basilar artery occlusion. Stroke 2011;41(4):722-26.
  36. Скворцова В.И., Голухов Г.Н., Губский Л.В. и др. Системная тромболитическая терапия при ишемическом инсульте // Журнал неврол. и псих. им. С.С. Корсакова 2006. № 106(12). С. 24-31.
  37. Скворцова В.И., Голухов Г.Н., Волынский Ю.Д. и др. Высокая эффективность селективного внутриартериального тромболизиса при лечении ишемического инсульта у больных с окклюзией артерий крупного калибра // Журнал неврол. и псих. им. С.С. Корсакова 2006. № 106(12). С. 32-40.
  38. Скворцова В.И., Шамалов Н.А., Анисимов К.В., Рамазанов Г.Р. Результаты внедрения тромболитической терапии при ишемическом инсульте в Российской Федерации // Журнал неврол. и псих. им. С.С. Корсакова. Инсульт 2010 № 12. Вып. 2. С. 17-22.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##